Mickovski, Ivana and Buklioska Ilievska, Daniela (2021) GLS-1027 for the prevention of severe pneumonitis caused by SARS-CoV-2 infection (COVID-19). [Project]
Full text not available from this repository.Abstract
This clinical trial will evaluate the safety, tolerability and efficacy of GLS-1027 in the prevention of severe pneumonitis caused by SARS-CoV-2 infection
Detailed Description: This Phase II randomized, double-blind, placebo-controlled, study will assess 2 different doses of GLS-1027 in the prevention of severe pneumonitis among those hospitalized with PCR confirmed SARS-CoV-2 infection. Subjects will be randomized at a 1:1:1 ratio to either Standard of Care (SOC) plus placebo, or SOC plus GLS-1027 at either 120 mg or 360 mg daily. Clinical status will be monitored through 56 days from the initiation of treatment.
| Item Type: | Project |
|---|---|
| Subjects: | Medical and Health Sciences > Clinical medicine |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Ivana Mickovski |
| Date Deposited: | 27 Feb 2024 11:54 |
| Last Modified: | 27 Feb 2024 11:54 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/33764 |
Actions (login required)
 |
View Item |